Source:http://linkedlifedata.com/resource/pubmed/id/19383625
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2009-7-7
|
pubmed:abstractText |
The novel coinhibitory receptor BTLA may have a regulatory role in maintaining peripheral tolerance; however, its role in autoimmune diabetes is unknown. In this study, we show that anti-BTLA mAb 6F7 selectively depleted pathogenic B and CD4+ T(H) cells; enhanced the proportion of cells with the forkhead box p3+ PD-1+CD4+ regulatory T phenotype; and increased the production of potentially protective (IL-10) and detrimental (IL-2, IFN-gamma) cytokines in NOD mice. As interactions between BTLA and PD-1 coinhibitory pathways have been described in the cardiac allograft model, we also investigated if these pathways may have significant interaction in autoimmune diabetes. Anti-BTLA inhibited anti-PD-1-potentiated total IL-12 (p40+p70) production, suggesting the possibility that anti-BTLA may have a greater effect in the setting of anti-PD-1-triggered diabetes. To test this, NOD mice at 4 and 10 weeks of age were treated with anti-BTLA mAb, anti-PD-1 mAb, both mAb, or isotype control and were monitored for diabetes development. Although anti-BTLA mAb delayed diabetes onset significantly in 10- but not 4-week-old NOD mice, anti-BTLA mAb attenuated anti-PD-1-induced diabetes in both age groups. Hence, strategies targeting BTLA+ lymphocytes or therapies enhancing the BTLA-negative cosignal may prove valuable in treating autoimmune diabetes.
|
pubmed:grant | |
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation,
http://linkedlifedata.com/resource/pubmed/chemical/BTLA protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/PD-1 antigen, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Pdcd1 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Programmed Cell Death 1 Receptor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Immunologic
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1938-3673
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
86
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
41-51
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:19383625-Animals,
pubmed-meshheading:19383625-Antibodies, Monoclonal,
pubmed-meshheading:19383625-Antigens, Differentiation,
pubmed-meshheading:19383625-B-Lymphocytes,
pubmed-meshheading:19383625-CD4-Positive T-Lymphocytes,
pubmed-meshheading:19383625-Diabetes Mellitus, Experimental,
pubmed-meshheading:19383625-Drug Interactions,
pubmed-meshheading:19383625-Immunophenotyping,
pubmed-meshheading:19383625-Interleukin-10,
pubmed-meshheading:19383625-Interleukin-12,
pubmed-meshheading:19383625-Lymphocyte Count,
pubmed-meshheading:19383625-Lymphocytes,
pubmed-meshheading:19383625-Mice,
pubmed-meshheading:19383625-Mice, Inbred NOD,
pubmed-meshheading:19383625-Programmed Cell Death 1 Receptor,
pubmed-meshheading:19383625-Receptors, Immunologic
|
pubmed:year |
2009
|
pubmed:articleTitle |
BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice.
|
pubmed:affiliation |
Surgical Medical Research Institute, Department of Surgery, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|